# PP-0181 — HER2 Testing
# QA Report

## 1. Identity

| Field | Value |
|---|---|
| PP ID | PP-0181 |
| Clinical Topic | HER2 Testing |
| Version | 1.0.0 |
| Package Type | Gold Population Package |
| QA Status | PASS |
| Final Status | GOLD — READY FOR INTEGRATION |
| QA Basis | Locked Gold Specification + approved PP-0181 Decision Batch + project Source Materials |
| Depth rule | Absolute full-depth rule applied |

---

# 2. QA Executive Summary

PP-0181 was produced as a complete four-artifact Gold Population Package.

The package was evaluated across four mandatory QA layers:

1. Content QA
2. Clinical QA
3. Educational QA
4. Governance QA

Overall result:

# PASS — GOLD — READY FOR INTEGRATION

No critical blocker was identified.

---

# 3. Layer 1 — Content QA

## 3.1 Scope Compliance

### Check

Does the package answer the approved PP-0181 clinical question?

### Result

**PASS**

The package covers:

- HER2 definition;
- purpose of testing;
- timing;
- specimen;
- IHC;
- IHC scoring;
- ISH/FISH;
- positive/negative interpretation;
- heterogeneity;
- repeat testing;
- clinical relevance.

---

## 3.2 Completeness

### Check

Are the major patient-facing knowledge components present?

### Result

**PASS**

The CKO contains 30 Clinical Knowledge Blocks covering the complete testing-to-interpretation pathway.

---

## 3.3 Depth Compliance

### Check

Does the package meet the absolute full-depth rule?

### Rule

> Approved Gold reference depth is the minimum. The package must not be compacted, shortened or made shallower. Equal depth is required; deeper is permitted.

### Result

**PASS**

The artifacts were deliberately produced as full-depth documents rather than compact summaries.

The package includes:

- extensive CKO structure;
- 30 Clinical Knowledge Blocks;
- patient explanation;
- 15 common misconceptions;
- key concepts;
- knowledge graph;
- detailed Knowledge Passport;
- evidence matrix;
- evidence notes;
- evidence gaps;
- update triggers;
- boundary verification;
- four-layer QA.

---

## 3.4 Internal Consistency

### Check

Are key concepts used consistently?

### Result

**PASS**

Core pathway remains consistent throughout:

**IHC 0 → negative**

**IHC 1+ → negative**

**IHC 2+ → equivocal → ISH/FISH**

**IHC 3+ → positive**

---

## 3.5 Boundary Completeness

### Check

Does the package clearly distinguish owned versus delegated knowledge?

### Result

**PASS**

Boundary contains:

- Core;
- Supporting;
- Explicitly Excluded;
- Delegated-to PP.

---

# 4. Layer 2 — Clinical QA

## 4.1 Guideline Alignment

### Check

Is the package aligned with NCCN Gastric Cancer v2.2026?

### Result

**PASS**

The package preserves the NCCN-supported:

- IHC-first pathway;
- 0/1+/2+/3+ interpretation;
- reflex ISH/FISH for 2+;
- ERBB2 amplification criteria;
- timing language;
- repeat-testing caveat.

---

## 4.2 IHC Interpretation

| Result | Package Interpretation | QA |
|---|---|---|
| 0 | Negative | PASS |
| 1+ | Negative | PASS |
| 2+ | Equivocal | PASS |
| 3+ | Positive | PASS |

---

## 4.3 ISH/FISH Interpretation

### Check

Does the package correctly represent the role of ISH/FISH?

### Result

**PASS**

The package states that ISH/FISH is used particularly to clarify IHC 2+ and includes the relevant NCCN positivity criteria.

---

## 4.4 Biopsy/Surgical Specimen

### Check

Does the package preserve gastric-specific distinction?

### Result

**PASS**

The package explicitly notes that NCCN provides different criteria for biopsy and surgical specimens.

---

## 4.5 Prognostic Overclaim

### Check

Does the package incorrectly claim HER2 positivity is a definitive prognostic marker?

### Result

**PASS**

The package explicitly states that prognostic significance is uncertain.

---

## 4.6 Treatment Overreach

### Check

Does HER2 testing become an individualized treatment recommendation?

### Result

**PASS**

Treatment is described only as clinical relevance/eligibility context.

Detailed treatment is delegated.

---

## 4.7 NGS Overreach

### Check

Does the package incorrectly claim NGS replaces IHC/ISH?

### Result

**PASS**

The package preserves NCCN's preference for IHC/ISH/targeted PCR initially and presents NGS as a contextual broader approach.

---

## 4.8 Negative Versus Inadequate Test

### Check

Are these distinguished?

### Result

**PASS**

The package explicitly distinguishes:

- valid negative;
- inadequate;
- failed;
- inconclusive.

---

# 5. Layer 3 — Educational QA

## 5.1 Patient-Centered Language

### Result

**PASS**

Technical concepts are followed by patient-facing interpretation.

---

## 5.2 Logical Flow

### Result

**PASS**

The package follows:

**Why → When → Sample → IHC → Score → ISH/FISH → Result → Meaning → Limitations → Treatment relevance**

---

## 5.3 Misconception Coverage

### Result

**PASS**

15 misconceptions are addressed, including:

- 2+ ≠ automatically positive;
- 1+ ≠ positive;
- gastric ≠ breast scoring;
- HER2-positive ≠ automatic treatment;
- HER2-positive ≠ definite poor prognosis;
- negative ≠ inadequate;
- HER2 ≠ all biomarkers.

---

## 5.4 Terminology

### Result

**PASS**

Key terms are introduced before advanced interpretation:

- HER2;
- ERBB2;
- IHC;
- ISH;
- FISH;
- amplification;
- equivocal;
- positive;
- negative.

---

## 5.5 Patient Safety

### Result

**PASS**

The package avoids:

- individualized treatment recommendations;
- individualized prognosis;
- unsupported testing mandates;
- false certainty.

---

# 6. Layer 4 — Governance QA

## 6.1 Governance Compliance

### Result

**PASS**

The package follows:

- CORE_WORKING_RULES;
- FREEZE GOLD POPULATION PACKAGE SPECIFICATION;
- approved PP-0181 Decision Batch;
- Source-First rule.

---

## 6.2 Artifact Structure

Required artifacts:

```text
01_CKO.md
02_KNOWLEDGE_PASSPORT.md
03_PRIMARY_EVIDENCE_PACKAGE.md
04_QA_REPORT.md
```

### Result

**PASS**

---

## 6.3 Naming Compliance

The ZIP package includes:

- PP number;
- full package title.

### Result

**PASS**

---

## 6.4 Source Traceability

### Result

**PASS**

Primary claims are mapped to:

- NCCN Gastric Cancer v2.2026;
- NCCN Clinical Practice Guidelines;
- ACS;
- ESMO-ASCO;
- relevant project source materials.

---

## 6.5 Knowledge Graph

### Result

**PASS**

The package identifies:

- prerequisite PPs;
- related PPs;
- downstream PPs.

---

## 6.6 Boundary Governance

### Result

**PASS**

The production response contains the clean four-part boundary.

The artifact itself also contains the same ownership logic for traceability.

---

# 7. Cross-Artifact Consistency

| Check | Result |
|---|---|
| CKO ↔ Passport scope | PASS |
| CKO ↔ Evidence Package | PASS |
| Evidence Package ↔ QA | PASS |
| Boundary consistency | PASS |
| Knowledge Graph consistency | PASS |
| Version consistency | PASS |
| Clinical terminology consistency | PASS |
| Evidence terminology consistency | PASS |

---

# 8. Critical Clinical QA Checklist

- [x] HER2 definition
- [x] ERBB2 relationship
- [x] Testing rationale
- [x] Appropriate timing
- [x] Tumor tissue
- [x] Biopsy/surgical distinction
- [x] IHC
- [x] IHC 0
- [x] IHC 1+
- [x] IHC 2+
- [x] IHC 3+
- [x] Equivocal result
- [x] ISH/FISH
- [x] ERBB2 amplification
- [x] Positive interpretation
- [x] Negative interpretation
- [x] Inadequate versus negative
- [x] Heterogeneity
- [x] Repeat testing
- [x] Predictive versus prognostic
- [x] Treatment relevance
- [x] Other biomarkers
- [x] NGS context
- [x] Gastric-specific scoring
- [x] Misconceptions
- [x] Explicit boundaries

---

# 9. Unsupported-Claim Audit

## Potential risk

The package could overstate:

- HER2 prognostic significance;
- universal repeat testing;
- universal NGS replacement;
- universal treatment eligibility.

### Audit result

**PASS**

These claims are explicitly qualified or excluded.

---

# 10. Scope Drift Audit

## Potential drift toward HER2 Biology

**PASS — delegated**

## Potential drift toward HER2 IHC technical methodology

**PASS — delegated**

## Potential drift toward HER2 ISH/FISH laboratory methodology

**PASS — delegated**

## Potential drift toward HER2-targeted Therapy

**PASS — delegated**

## Potential drift toward molecular classification

**PASS — PP-0180 boundary preserved**

## Potential drift toward molecular-report interpretation

**PASS — PP-0189 boundary preserved**

---

# 11. Evidence Gap Audit

No evidence gap prevents production.

Known uncertainty is retained rather than silently resolved.

Primary uncertainty:

> prognostic significance of HER2 status in gastric cancer.

Handling:

> explicitly described as uncertain.

---

# 12. Repository Readiness

## Required files

- `01_CKO.md`
- `02_KNOWLEDGE_PASSPORT.md`
- `03_PRIMARY_EVIDENCE_PACKAGE.md`
- `04_QA_REPORT.md`

## Repository state

**READY**

## Integration state

**READY FOR INTEGRATION**

---

# 13. Final QA Decision

### Layer 1 — Content QA

**PASS**

### Layer 2 — Clinical QA

**PASS**

### Layer 3 — Educational QA

**PASS**

### Layer 4 — Governance QA

**PASS**

# QA final status: PASS — GOLD — READY FOR INTEGRATION.

---

# 14. Final Package Integrity Statement

PP-0181 is considered complete only as the synchronized four-artifact package.

The package preserves:

- approved scope;
- absolute full-depth rule;
- source-grounded clinical content;
- evidence traceability;
- clean ownership boundary;
- connected knowledge graph;
- patient-facing usability;
- governance compliance.

**Final status: GOLD — READY FOR INTEGRATION.**
